(UroToday.com) The advanced prostate cancer session at the 2021 American Urologic Association (AUA) annual meeting included a presentation by Dr. Scott Tagawa who discussed long-term follow-up and prognostic factor analysis among men with mCRPC who received 177Lu-PSMA therapy. PSMA-targeted radionuclide therapy has recently emerged as a promising treatment modality for advanced prostate cancer. PSMA may be targeted with antibodies (J591) or small molecule ligands (PSMA-617) labeled with the beta-emitting radionuclide lutecium-177. 177Lu-PSMA is a promising investigational treatment for men with mCRPC, however optimal selection and biomarkers remain to be defined. At today’s session, Dr. Tagawa and colleagues reported results of a combined analysis of men with mCRPC treated on sequential prospective clinical trials of PSMA-targeted 177Lu.